It has been reported that when the HSP70 vaccine and sPD-1—which are used to treat cancer and to block PD-L1, respectively—are combined, mice experience a significantly prolonged survival time compared to mice treated with HSP70 or sPD-1 separately [25]. The gene discussed is HOXD13; the disease is cancer.